Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX)
RXRX Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
53.50%
Analyst Rating:
BUY
Analyst Forecast (1yr):
132%
RXRX Stock Analysis
RXRX
PE Ratio:
RXRX
PEG Ratio:
Not Available
RXRX
Forward EPS Growth (12 month):
0.00%
RXRX
PS Ratio:
23.4
RXRX
PSG Ratio:
0.3
RXRX
Forward Revenue Growth (12 month):
70.60%
RXRX Articles
Hugh Pambrun |
June 26, 2026
Cathie Wood is Betting Big on These 8 Stocks
CBRS, HOOD, PLTR, RXRX, COIN, XE, CRCL, BLSH
